Clene Provides Update on ALS Clinical Development Meeting With FDA
SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq:CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today provided an ALS regulatory update from its recent meeting with the U.S. Food and Drug Administration (FDA).
Related news for (CLNN)
- Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights
- Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session
- Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
- Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
- Clene and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL Reduction